Pioneering the Future of Liquid Cooling: Walrus Pump's 2025 COMPUTEX Debut
TAIPEI, Taiwan, May 27, 2025 (GLOBE NEWSWIRE) -- Leading pump brand Walrus Pump Co., Ltd. (6982) is making its debut at 2025 Computex Taipei, taking place from May 20 to 23. The company has continued to advance its smart pump technology and offers comprehensive pump solutions. In addition to everyday and manufacturing applications, Walrus has expanded into advanced sectors such as data centers, EV charging station cooling, and heat exchange systems. Through continuous innovation and strategic market deployment, the Company has solidified its position as a leader in Taiwan's pump market.
In Q1 2025, the company reported consolidated revenue of NT$429 million, representing a year-over-year increase of 17.84%. Gross profit reached NT$121 million (up 15.24% YoY), with a gross margin of 29%. Net profit after tax was NT$32 million, up 38.45% YoY, and earnings per share (EPS) came in at NT$0.80, up 21.21% YoY. This strong Q1 performance highlights the company's solid operational momentum.
Walrus operates two major production bases in Taiwan – Sanzhi in New Taipei and the Zhengyi Plant in Luzhu District, Kaohsiung. Its new Global Plant in Kaohsiung is expected to receive its operating permit and begin small-scale production in the second half of this year. This facility will feature smart manufacturing, integrating production line data through a Manufacturing Execution System (MES) and incorporating an automated warehouse system – enhancements expected to significantly boost both production capacity and inventory management efficiency. In parallel, the Company's subsidiary, Suzhou Walrus, continues to serve the Mainland China market while expanding into ASEAN regions, meeting diverse pump order demands from both domestic and international clients.
With the booming development of AI computing and high-density data centers, cooling efficiency has become a key component of next-generation infrastructure. At Computex Taipei, Walrus is officially unveiling two innovative pump series: the 'TPMS Slim Motor Multistage Centrifugal Pump series' and the 'CMP Glandless Variable-Speed Pump series'. The TPMS Slim Motor Multistage Centrifugal Pump series features intelligent control capabilities, dynamically adjusting pump speed and chilled water flow based on IT heat loads. This makes it an ideal solution that meets the dual demands of energy efficiency and modular cooling systems in modern data centers – striking a balance between cooling performance and operational costs. Meanwhile, the CMP series is compatible with a variety of coolants. Its glandless design significantly reduces leakage risks and maintenance costs, making it a key component in the next generation of high-reliability liquid cooling solutions for data centers. Both of these products align with ESG goals by focusing on energy savings, smart control, and efficient space utilization – positioning them as driving forces in the global upgrade of data center infrastructure.
In terms of R&D, Walrus operates a dual-power Pump Dynamic Laboratory certified by both TAF and TÜV. This cutting-edge facility provides validation and testing technologies that can be tailored to meet customer-specific needs for server modular system integration, ensuring precise optimization of pump head, flow rate, and motor performance.
To strengthen its digital strategy, Walrus integrates IoT technology into pump automation and smart monitoring, offering remote control and predictive maintenance to enhance product reliability and safety. Additionally, Walrus provides timely customer support through its AI-powered service platform and dedicated after-sales service team, ensuring fast responses to maintenance needs.
As global demand for server cooling surges, Walrus is showcasing its ambitions to enter the high-end server cooling market at this year's exhibition. Since 2024, it has steadily received orders for liquid cooling pumps for server applications and continues to invest in the development of Brushless DC (BLDC) motors. With strong R&D capabilities and highly competitive product quality, Walrus is poised to become the go-to partner for many domestic thermal module manufacturers. It also aims to strengthen its overseas presence through brand-driven market expansion, driving sustained growth and promising future performance.
Press Contact:
Walrus Pump Chang, Teng-Hsi (02)2768-0001
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
26 minutes ago
- Forbes
‘Mecha Break' Will Finally Launch At The Start Of July
It's taken a while, but after various early access betas, Mecha Break will finally launch this July. As with all early access releases, the initial response to Mecha Break was pretty mixed. From network issues to other problems, fans complained, and it seems that those complaints were listened to and seemingly acted upon. That's the point, really. The whole purpose of releasing your game early, especially a multiplayer one, is to find out what the issues are going to be before launch and then fix them. Obviously, you can get pretty far on your own, figuring out the main issues before releasing a game to the public, but early access releases will always help a multiplayer game find its feet eventually. After all, this is a high-speed mecha shooting game, and that's a tough thing to get right, especially as games are already an abstract ruleset in and of themselves. Adding mecha to that, which are also an abstracted ruleset of their own in terms of functionality, doesn't just double the complexity of the game's design, it squares it. In this instance, Mecha Break is also a high-speed and quite aerial mecha game, and that's a lot to balance out before release. Thankfully, the game is using proper Japanese mecha designers for the game's mecha, although they have been stylized somewhat. In any case, Mecha Break is now almost here, and I am very curious to see how it does. The mecha styling and high-speed gameplay make me think this will find its market mostly in Asia, but I hope Western gamers give it a chance, too. Mecha Break will be released for PC, via Steam, and Xbox Series X|S on July 1. Follow me on X, Facebook and YouTube. I also manage Mecha Damashii and am currently featured in the Giant Robots exhibition currently touring Japan.
Bloomberg
an hour ago
- Bloomberg
Trump Says Xi to Restart Rare Earth Flows, Sets Date for Talks
Supply Lines is a daily newsletter that tracks global trade. Sign up here. President Donald Trump said his Chinese counterpart Xi Jinping had agreed to restart the flow of rare-earth materials, as negotiators from the two nations prepare to resume trade talks on June 9 in London.
Yahoo
an hour ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
